Literature DB >> 1309276

A system for the high efficiency replication of HIV-1 in neural cells and its application to anti-viral evaluation.

B Volsky1, K Sakai, M M Reddy, D J Volsky.   

Abstract

Stable transfection of H4 neuroglioma cells with the Epstein-Barr virus-based eucaryotic CD4 expression vector pKS286 generated the cell line, H4/CD4, in which greater than 90% of cells express surface CD4 receptors. Optimal conditions for infection of H4/CD4 cells with HIV-1 were determined; these included a cocultivation with growth-arrested, chronically infected T cells. Under these conditions, 3-days after infection up to 50% of H4/CD4 cells expressed HIV-1 antigens as detected by immunofluorescence assay, the number of intracellular HIV-1 RNA copies reached 10(3) molecules per cell as determined by liquid hybridization, and virus production ranged from 0.2 to 1.0 micrograms HIV-1 p24 core antigen per ml of culture supernatant, comparable to that measured under the same conditions in HIV-1 infected T cells. Giant cells and cytolysis were common. Inhibition of HIV-1 infection by nucleoside analogues in H4/CD4 cells was comparable to that in T cells, suggesting that the early stages of HIV-1 infection were similar in both cell systems. Infection in the presence of soluble CD4 reduced HIV-1 expression to the levels determined in CD4-negative H4 cells. This system may be useful for screening of drugs intended to block HIV-1 replication in the brain and for the evaluation of the HIV-1 life cycle in brain cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309276     DOI: 10.1016/0042-6822(92)90086-5

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells.

Authors:  M Shahabuddin; G Bentsman; B Volsky; I Rodriguez; D J Volsky
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

2.  Correlation of specific virus-astrocyte interactions and cytopathic effects induced by ts1, a neurovirulent mutant of Moloney murine leukemia virus.

Authors:  E Shikova; Y C Lin; K Saha; B R Brooks; P K Wong
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

3.  Opportunistic DNA Recombination With Epstein-Barr Virus at Sites of Control Region Rearrangements Mediating JC Virus Neurovirulence.

Authors:  Margaret J Wortman; Patric S Lundberg; Ayuna V Dagdanova; Pranav Venkataraman; Dianne C Daniel; Edward M Johnson
Journal:  J Infect Dis       Date:  2015-12-21       Impact factor: 5.226

4.  Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes.

Authors:  M Canki; J N Thai; W Chao; A Ghorpade; M J Potash; D J Volsky
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist.

Authors:  M Shahabuddin; B Volsky; M C Hsu; D J Volsky
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

6.  TAR-independent replication of human immunodeficiency virus type 1 in glial cells.

Authors:  O Bagasra; K Khalili; T Seshamma; J P Taylor; R J Pomerantz
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 7.  Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis.

Authors:  Zhuying Wang; Gusta Trillo-Pazos; Seon-Young Kim; Mario Canki; Susan Morgello; Leroy R Sharer; Harris A Gelbard; Zao-Zhong Su; Dong-Chul Kang; Andrew I Brooks; Paul B Fisher; David J Volsky
Journal:  J Neurovirol       Date:  2004       Impact factor: 2.643

8.  Inhibition of human immunodeficiency virus type-1 (HIV-1) glycoprotein-mediated cell-cell fusion by immunor (IM28).

Authors:  Donatien Mavoungou; Virginie Poaty-Mavoungou; Marie-Yvonne Akoume; Brice Ongali; Elie Mavoungou
Journal:  Virol J       Date:  2005-02-11       Impact factor: 4.099

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.